
Antibodies, Год журнала: 2025, Номер 14(2), С. 35 - 35
Опубликована: Апрель 11, 2025
Monoclonal antibodies (mAbs) targeting various pathways in cancer therapy play crucial roles enhancing the immune system’s ability to recognise and eliminate tumour cells. These therapies are designed either block inhibitory checkpoint or target specific cell markers for direct destruction. Additionally, mAbs can modulate microenvironment, enhance antibody-dependent cellular cytotoxicity, inhibit angiogenesis, further amplifying their therapeutic impact. Below is a summary of monoclonal key pathways, along with indications mechanisms action, which reviewed based on mechanisms.
Язык: Английский